Table 2

Multivariate Cox regression analysis of clinicopathological parameters and aquaporin 3 protein expression by the tumour regarding recurrence free (a), progression-free (b) and cancer-specific survival (c) in stage T1 urothelial bladder carcinoma
HR (CI 95%) p-value
a.
Genderfemale vs. male 0.50 (0.11 – 2.29) 0.372
Ageper year 1.01 (0.97 – 1.05) 0.770
Recurrent diseaseyes vs. no (initial finding) 0.58 (0.10 – 3.50) 0.552
Grading WHO 1973G3 vs. G2 1.08 (0.25 – 4.67) 0.916
Associated CISyes vs. no 1.58 (0.63 – 3.97) 0.328
Focalitymultifocal vs. unifocal 0.33 (0.07 – 1.65) 0.177
Tumour size≥3cm vs. <3cm 0.68 (0.25 – 1.92) 0.485
BCG instillations≤6 vs. >6 0.77 (0.23 – 2.57) 0.667
AQP3negative vs. positive expression 0.81 (0.29 – 2.25) 0.552
b.
Genderfemale vs. male 0.42 (0.03 – 5.27) 0.500
Ageper year 1.01 (0.95 – 1.08) 0.697
Recurrent diseaseyes vs. no (initial finding) 4.08 (0.24 – 69.74) 0.332
Grading WHO 1973G3 vs. G2 0.71 (0.28 – 1.79) 0.469
Associated CISyes vs. no 1.40 (0.28 – 7.12) 0.683
Focalitymultifocal vs. unifocal constant 0.976
Tumour size≥3cm vs. <3cm 2.64 (0.30 – 22.97) 0.380
BCG instillations≤6 vs. >6 constant 0.977
AQP3negative vs. positive expression 7.58 (1.29 – 44.68) 0.025
c.
Genderfemale vs. male constant 0.972
Ageper year 1.03 (0.97 – 1.09) 0.338
Recurrent diseaseyes vs. no (initial finding) constant 0.999
Grading WHO 1973G3 vs. G2 constant 0.975
Associated CISyes vs. no 0.79 (0.18 – 3.46) 0.756
Focalitymultifocal vs. unifocal constant 0.976
Tumour size≥3cm vs. <3cm 2.98 (0.35 – 24.86) 0.316
BCG instillations≤6 vs. >6 constant
AQP3negative vs. positive expression 1.16 (0.26 – 5.15) 0.849

Reference in italics; p-values <0.05 are indicated in bold; AQP3 aquaporin 3 protein; BCG Bacillus Calmette-Guérin; CI confidence interval; CIS carcinoma in situ; HR hazard ratio; WHO world health organisation.

Otto et al.

Otto et al. BMC Cancer 2012 12:459   doi:10.1186/1471-2407-12-459

Open Data